Contents
In line with its mission, the Editorial Board of MedTvoiLokony makes every effort to provide reliable medical content supported by the latest scientific knowledge. The additional flag “Checked Content” indicates that the article has been reviewed by or written directly by a physician. This two-step verification: a medical journalist and a doctor allows us to provide the highest quality content in line with current medical knowledge.
Our commitment in this area has been appreciated, among others, by by the Association of Journalists for Health, which awarded the Editorial Board of MedTvoiLokony with the honorary title of the Great Educator.
The European Medicines Agency (EMA) on Thursday, March 11, authorized the COVID-19 vaccine from Johnson & Johnson. It can be given to people over 18 years of age. This means that the member states of the European Union will be able to vaccinate with this preparation. The first doses will be able to reach Poland in the second half of April.
- Johnson & Johnson vaccine authorized for use in the EU
- It is a preparation that is administered in a single dose – unlike the vaccines by Pfizer, Moderna and AstraZeneca.
- We can expect the first delivery of the J&J preparation to Poland in the second half of April, the president of the Governmental Agency for Strategic Reserves, Michał Kuczmierowski, told PAP
- You can find more such stories on the Onet homepage.
The Johnson & Johnson vaccine against COVID-19 in April may be in Poland
On Thursday, March 11, the European Medicines Agency (EMA) issued an opinion on the Johnson & Johnson vaccine. The preparation was given the green light, PAP reported. The EMA will now recommend the European Commission to approve the use of this vaccine in member countries. This means that four COVID-19 vaccines will be approved for use in the European Union: Pfizer, Moderna, AstraZeneca and Johnson & Johnson.
– The provision in the contract with J&J is that the preparation will be delivered one month from the confirmation of the delivery schedule. We have not yet received the schedule, so it can be expected that the first delivery will take place in the second half of April – Michał Kuczmierowski, president of the Governmental Reserve Agency, told PAP.
Johnson & Johnson vaccine for COVID-19 – how many doses, how effective
The formulation from Johnson & Johnson is a vector vaccine (such as AstraZeneca). It is based on the use of fragments of other viruses to trigger an immune response against a specific virus – in this case, the SARS-COV-2 coronavirus. Vector vaccines are a relatively new technology.
- Check also: COVID-19 vaccines. What do we know about them and how do they differ?
Contrary to other preparations that have been approved for use in the European Union, Johnson & Johnson vaccine is single dose. It is not necessary to administer a second dose of the preparation to gain resistance to COVID-19.
When it comes to the effectiveness of the Johnson & Johnson vaccine, it is 66 percent., as reported in January by Janssen, which belongs to Johnson & Johnson. This is less than the Pfizer and Moderna vaccines, which are estimated to be more than 90 percent effective. Johnson & Johnson, however, is more effective than the AstraZeneca vaccine (about 60 percent).
The Johnson & Johnson vaccine is relatively easy to transport. It does not require storage at such low temperatures as other preparations. Johnson & Johnson’s agent is relatively effective in South Africa, which means it can cope with the South African variant.
Johnson & Johnson COVID-19 vaccine – effectiveness
On January 29, Johnson & Johnson announced that the COVID-19 vaccine is 66 percent effective. The results were based on the results of the third phase of the clinical trial. The research was conducted in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and the United States. 44 thousand people took part in it. 325 volunteers.
- Also read: Can those vaccinated against COVID-19 continue to infect?
The Johnson & Johnson vaccine reduced the risk of developing moderate to severe COVID-19 by 66 percent in all subjects, regardless of geographic region or variant of the virus they were infected with. for 28 days after vaccination. At 85 percent its effectiveness in preventing severe disease caused by the coronavirus was assessed. When it comes to protection against hospitalization in the course of COVID-19, it amounted to 100%. in the third phase of research.
Efficacy in people in the study varied by geographic area. In the US it was 72%, in Latin America it was 66%, and in South Africa – 57%.
The US approved the COVID-19 Johnson & Johnson vaccine in late February
In late February, the US Federal Food and Drug Administration (FDA) approved the Johnson & Johnson vaccine for use in the United States. Thus, the preparation became the third that Americans are vaccinated with – after the Pfizer and Moderna preparations.
By the end of March, Johnson & Johnson is expected to deliver 20 million doses of the COVID-19 vaccine to the US.
Also read:
- How to prepare for the COVID-19 vaccination? Family doctors’ advice for seniors
- What About Easter in a Pandemic? Experts are under no illusions
- Where can I get vaccinated against COVID-19? List of vaccination points
- What determines the effectiveness of vaccinations
- British Coronavirus Mutation More Deadly? There is new evidence
The content of the medTvoiLokony website is intended to improve, not replace, the contact between the Website User and their doctor. The website is intended for informational and educational purposes only. Before following the specialist knowledge, in particular medical advice, contained on our Website, you must consult a doctor. The Administrator does not bear any consequences resulting from the use of information contained on the Website. Do you need a medical consultation or an e-prescription? Go to halodoctor.pl, where you will get online help – quickly, safely and without leaving your home.Now you can use e-consultation also free of charge under the National Health Fund.